Protalix BioTherapeutics, Inc.
PLX
$2.81
-$0.045-1.58%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -18.47% | -28.22% | -43.59% | 45.00% | 37.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.47% | -28.22% | -43.59% | 45.00% | 37.48% |
| Cost of Revenue | 5.82% | 77.26% | 37.98% | 35.19% | 17.30% |
| Gross Profit | -31.60% | -65.23% | -74.88% | 51.67% | 51.58% |
| SG&A Expenses | -18.49% | -4.15% | 10.08% | 28.16% | 27.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.09% | 9.05% | -4.14% | -5.76% | -9.26% |
| Operating Income | -62.55% | -165.59% | -219.79% | 159.27% | 180.37% |
| Income Before Tax | -51.51% | -181.38% | -252.51% | 144.99% | 159.50% |
| Income Tax Expenses | 381.10% | -98.46% | -144.14% | -110.90% | -52.08% |
| Earnings from Continuing Operations | -64.73% | -190.49% | -265.08% | 143.42% | 155.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.73% | -190.49% | -265.08% | 143.42% | 155.68% |
| EBIT | -62.55% | -165.59% | -219.79% | 159.27% | 180.37% |
| EBITDA | -55.19% | -151.75% | -200.47% | 174.33% | 197.68% |
| EPS Basic | -65.12% | -198.07% | -328.54% | 137.23% | 140.51% |
| Normalized Basic EPS | -53.04% | -185.23% | -295.05% | 138.66% | 143.43% |
| EPS Diluted | -85.22% | -463.52% | -2,230.10% | 106.63% | 109.45% |
| Normalized Diluted EPS | -71.64% | -234.38% | -506.35% | 120.91% | 125.62% |
| Average Basic Shares Outstanding | 7.63% | 17.92% | 29.28% | 38.77% | 39.07% |
| Average Diluted Shares Outstanding | 11.72% | 8.92% | 25.45% | 52.17% | 53.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |